CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Goadsby, P. [1 ,2 ,3 ]
Dodick, D. [4 ]
Spierings, E. [5 ,6 ,7 ]
Scherer, J. [8 ]
Sweeney, S. [9 ]
Grayzel, D. [9 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Clin Res Facil KCL, London WC2R 2LS, England
[2] Kings Coll London, Dept Neurol UCSF, London WC2R 2LS, England
[3] Univ Calif San Francisco, London, England
[4] Mayo Clin, Dept Neurol, Phoenix, AZ USA
[5] Harvard Univ, Brigham & Womens Hosp, Dept Neurol BWH, Sch Med, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Headache & Face Pain Program, Sch Med, Boston, MA 02115 USA
[7] Tufts Sch Dent Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Arteaus Therapeut, Cambridge, MA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2014年 / 15卷
关键词：
Placebo; Migraine; Calcitonin; Injection Site; Secondary Endpoint;
D O I：
10.1186/1129-2377-15-S1-G10
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTI-0178
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine
    Whitmarsh, TE
    ColestonShields, DM
    Steiner, TJ
    CEPHALALGIA, 1997, 17 (05) : 600 - 604
  • [22] Oxcarbazepine in migraine headache - A double-blind, randomized, placebo-controlled study
    Silberstein, S.
    Saper, J.
    Berenson, F.
    Somogyi, M.
    McCague, K.
    D'Souza, J.
    NEUROLOGY, 2008, 70 (07) : 548 - 555
  • [23] Topiramate for migraine prevention: a randomized, double-blind, placebo-controlled, multiple-dose study
    Brandes, J
    Neto, W
    Jacobs, D
    Bhattacharaya, S
    CEPHALALGIA, 2003, 23 (07) : 694 - 694
  • [24] Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP Peptide Antibody in the Prevention of Frequent Episodic Migraine
    Goadsby, P. J.
    Dodick, D.
    Silberstein, S.
    Lipton, R. B.
    Olesen, J.
    Ashina, M.
    Wilks, K.
    Kudrow, D.
    Kroll, R.
    Kohrman, B.
    Bargar, R.
    Hirman, J.
    Smith, J.
    HEADACHE, 2014, 54 (08): : 1420 - 1420
  • [25] Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine
    Goadsby, Peter
    Dodick, David
    Silberstein, Stephen
    Lipton, Richard
    Olesen, Jes
    Ashina, Messoud
    Wilks, Kerri
    Kudrow, David
    Krolll, Robin
    Kohrman, Bruce
    Bargar, Robert
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2014, 83 (02) : E40 - E40
  • [26] Randomized, Double-blind, Placebo-controlled Trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine.
    Dodick, David
    Goadsby, Peter
    Silberstein, Stephen
    Lipton, Richard
    Hirman, Joe
    Smith, Jeff
    NEUROLOGY, 2017, 88
  • [27] A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine
    Sun, H.
    Silberstein, S.
    Dodick, D. W.
    Reuter, U.
    Ashina, M.
    Saper, J. R.
    Cady, R.
    Chon, Y.
    Dietrich, J.
    Lenz, R.
    HEADACHE, 2015, 55 : 132 - 132
  • [28] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Hu, Bo
    Li, Gang
    Li, Xiaohong
    Wu, Shan
    Yu, Tingmin
    Li, Xiang
    Zhao, Hongru
    Jia, Zhihua
    Zhuang, Junpeng
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [29] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Bo Hu
    Gang Li
    Xiaohong Li
    Shan Wu
    Tingmin Yu
    Xiang Li
    Hongru Zhao
    Zhihua Jia
    Junpeng Zhuang
    Shengyuan Yu
    The Journal of Headache and Pain, 2022, 23
  • [30] Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
    Goadsby, Peter J.
    Wietecha, Linda A.
    Dennehy, Ellen B.
    Kuca, Bernice
    Case, Michael G.
    Aurora, Sheena K.
    Gaul, Charly
    BRAIN, 2019, 142 : 1894 - 1904
12345